Claudia Centrone
Overview
Explore the profile of Claudia Centrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricci U, Ciappi D, Carboni I, Centrone C, Giotti I, Petti M, et al.
Genes (Basel)
. 2024 Jun;
15(6).
PMID: 38927695
The quantification of human DNA extracts from forensic samples plays a key role in the forensic genetics process, ensuring maximum efficiency and avoiding repeated analyses, over-amplified samples, or unnecessary examinations....
2.
Terlizzi V, Pesce E, Capurro V, Tomati V, Lena M, Pastorino C, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047546
S737F is a Cystic Fibrosis (CF) transmembrane conductance regulator (CFTR) missense variant. The aim of our study was to describe the clinical features of a cohort of individuals carrying this...
3.
Terlizzi V, Centrone C, Ferrari B, Castellani C, Gunawardena T, Taccetti G, et al.
J Pers Med
. 2022 Sep;
12(9).
PMID: 36143206
Previous studies reported the influence of variants in F508del cystic fibrosis (CF) patients in their responses to modulators. The current study is a prospective, observational study involving three patients with...
4.
Bianchimani C, Dolce D, Centrone C, Campana S, Ravenni N, Orioli T, et al.
Int J Neonatal Screen
. 2022 Aug;
8(3).
PMID: 35997436
Pancreatitis-Associated Protein (PAP)-based Cystic Fibrosis (CF) newborn bloodspot screening (NBS) protocols detect less CFTR-Related Metabolic Syndrome (CRMS)/CF Screen Positive, Inconclusive Diagnosis (CFSPID). We prospectively evaluated the impact of PAP as...
5.
Terlizzi V, Centrone C, Botti M, Taccetti G
Mol Genet Genomic Med
. 2022 Aug;
10(9):e2033.
PMID: 35962622
No abstract available.
6.
Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, et al.
J Cyst Fibros
. 2022 May;
21(5):850-855.
PMID: 35523714
Background: In recent years, patients with cystic fibrosis (CF) conductance regulator (CFTR) variant poly(T) sequences have been increasingly reported with a wide spectrum of clinical severity. We describe the long-term...
7.
Botti M, Terlizzi V, Francalanci M, Dolce D, Cavicchi M, Neri A, et al.
Ital J Pediatr
. 2021 Jan;
47(1):2.
PMID: 33407736
Background: Cystic fibrosis (CF) is a life-threatening disease affecting about 1:3000 newborns in Caucasian populations. The introduction of newborn screening for cystic fibrosis (CF NBS) has improved the clinical outcomes...
8.
Taccetti G, Botti M, Terlizzi V, Cavicchi M, Neri A, Galici V, et al.
Diagnostics (Basel)
. 2020 Jul;
10(7).
PMID: 32630227
Cystic fibrosis (CF) is a life-threatening and common genetic disorder. Cystic fibrosis newborn screening (CF NBS) has been implemented in many countries over the last 30 years, becoming a widely...
9.
Terlizzi V, Mergni G, Centrone C, Festini F, Taccetti G
Pediatr Pulmonol
. 2020 Mar;
55(5):1089-1093.
PMID: 32150665
No abstract available.
10.
Terlizzi V, Mergni G, Buzzetti R, Centrone C, Zavataro L, Braggion C
J Cyst Fibros
. 2019 Apr;
18(4):484-490.
PMID: 31005549
Objective: The implementation of cystic fibrosis (CF) newborn screening (NBS) has led to identification of infants with a positive NBS test but inconclusive diagnosis classified as "CF screen positive, inconclusive...